Q3 report card of multinational pharmaceutical companies announced: MSD China soared 90% Pfizer performance reversed

Adjustment of medical insurance catalogue and landing of volume purchase Have begun to adapt to the domestic "rules of the game" of the "big guys", what on earth for the performance of the "battle"? Which products are their "leaders"? With the gradual appearance of the third quarter report, the performance of multinational pharmaceutical companies in the past half year of 2019 has also appeared one by one In terms of the performance of the Chinese market, MSD's growth of 90% is beyond the reach of other multinational pharmaceutical companies, while Roche, Lilly and AstraZeneca are in hot pursuit of 53%, 33% and 40% respectively Pfizer, whose performance in China fell by 20% in the second quarter, achieved positive growth through structural adjustment, new drug remedy and other measures Adjustment of medical insurance catalogue and landing of volume purchase It can be seen that, regardless of the size, more and more multinational pharmaceutical companies have begun to adapt to the "rules of the game" of the domestic market At the same time, more and more MNC global executives began to emphasize "the importance of the Chinese market" frequently in public, and more and more enterprises began to really "tailor" market strategies for China The change of personnel and the adjustment of structure make foreign pharmaceutical enterprises integrate into the Chinese pharmaceutical market more deeply So, have begun to integrate into the domestic "rules of the game" of the "big guys", what on earth is the performance of the "battle"? Which products are their "leaders"? What is their logic behind the collective strategy of renewing China? The global sales revenue of MSD in the first three quarters was US $34.972 billion, of which Q3 sales revenue was US $12.4 billion, up 15% year on year Among them, the sales of keytruda, the most popular star drug, reached US $3.07 billion in Q3, an increase of 64% over the same period of last year, and the sales of keytruda in the first three quarters of 2019 was US $7.973 billion Under the stimulation of good performance, MSD raised its full year performance expectation to US $46.5-47 billion Another highlight of MSD's third quarter report is that the revenue of China's business in the first three quarters of 2019 reached US $2.368 billion, of which the sales revenue of Q3 reached US $898 million, up 90% year on year China continues to maintain its leading position in the pharmaceutical business, Mr moshadong said in the financial statement The bright performance in China is mainly driven by keytruda and nine valent HPV vaccine Keytruda has listed three indications in China, with a sales volume of about 1 billion yuan in the first half of the year, especially after being approved as the first-line lung cancer therapy, drug K will undoubtedly continue to maintain its first mover advantage in the field of lung cancer The global performance of vaccines increased by 18% driven by jiadaxiu and children's vaccines, among which the growth of China contributed a lot In April 2018, MSD nine price HPV vaccine submitted an application for listing, and got the approval for listing 28 days later Due to its popularity, in May 2018, Hong Kong market also had a situation where nine price HPV vaccine was hard to obtain in one shot In the third quarter, Pfizer, the world's largest pharmaceutical company, earned $12.7 billion in revenue, with a net profit of $7.68 billion, which exceeded the market's expected revenue of $12.261 billion and $3.297 billion As a result, Pfizer's share price also rose sharply after the results were released However, Pfizer's global sales fell 5% in the third quarter from $13.3 billion in the same period last year, due to the loss of exclusive U.S patent rights by lerica Pfizer's revenue, which had just been "spun off" a while ago, fell 26% year-on-year Lerika has a revenue of 527 million US dollars, but nine companies, including alembic pharmaceutical, alkem laboratory, amneal pharmaceutical company, Reddy's laboratory, invagen pharmaceutical company, MSN laboratory Co., Ltd., rise pharmaceutical company, sciegen pharmaceutical company and Teva pharmaceutical company, have begun to covet the product that sold 5 billion US dollars last year Just one day before the release of the third quarter report, the management of puqiang China announced the adjustment of business team structure and the collective resignation of the top five sales directors This is not the first major change in personnel of puqiang this year In September, Pfizer puqiang announced that Wu Feng, general manager of China, would leave his post and appointed Huang Hai, the head of marketing department of puqiang China, as the chief operating officer of puqiang China As the business with the highest proportion of performance in China, from the formal establishment to the global headquarters settled in Shanghai, and then to "marry" mylan, within less than a year, the business of puqiang has been constantly changing In the first round of belt purchase, two main varieties of Pfizer, atorvastatin and amlodipine besylate, were not awarded With the implementation of the policy, Pfizer also realized the impact of belt purchase Although Pfizer still failed to win the bid in the procurement of the second wheel belt volume, in the conference call, Frank d'amelio, Pfizer's financial director, said that the general strength "can reduce the impact of 4 + 7 by expanding the national region" According to the report, Pfizer reversed its negative growth of 20% in the last quarter in China and achieved 2% growth in China Pfizer CEO Albert bourla said in a conference call that in the third quarter of 2019, Pfizer's operations in China increased by 42%, and the revenue of biopharmaceutical business was larger than that of general strength According to the financial report, compared with 2018, Pfizer expects that the revenue of generic pharmaceutical business in China will achieve the highest median growth in 2019 In the previous "hospital 2018 drug use monitoring report" released by China Pharmaceutical Association, Pfizer still firmly occupies the "dominant position" in medical institutions, ranking first in the purchase volume with 3.75% of the total On October 16, Roche Group released the third quarter of 2019 financial report At a constant exchange rate, the group's sales in the first nine months of this year reached CHF 46.1 billion (US $47.1 billion), up 10% year on year The sales volume of pharmaceutical business was CHF 36.559 billion, up 12% over the same period, while the sales volume of diagnostic business was CHF 9.507 billion, up 4% over the same period In the pharmaceutical business, there are four most eye-catching new drugs: ocrevizumab, a new multiple sclerosis drug, with a performance of 2664 million Swiss francs in the first nine months; hemlibra shuyoulile, a new hemophilia drug, with a performance of 921 million Swiss francs in the first nine months; atezolizumab, a new tumor immune antibody, with a performance of 1297 million Swiss francs in the first nine months; perjeta, a new breast cancer drug In the first nine months, the performance was 2.665 billion Swiss francs Under the threat of biological similar drugs, the performance of rituximab and trastuzumab in the global market has declined It is worth noting that Herceptin, avidin and rituximab have been the "troika" for many years to drive the growth of Roche's China's performance, and they have maintained a strong growth after entering the national medical insurance catalog in 2017 In the first half of 2019, avidin grew by 61% in China, rituximab by 21% and Herceptin by 144% Driven by these products, Roche's mainland China market and Hong Kong market showed outstanding performance, with the first nine months' performance increasing 53% to 2.563 billion Swiss francs (18.378 billion yuan) In addition, the new drugs pajite and ansanza have also performed well after being launched in China Roche has planned to introduce several new products in China in 2019 On October 21, Roche's Shanghai innovation center, invested 863 million yuan in three years, was completed The completion and operation of Roche Shanghai innovation center means that China will not only be Roche's key market for clinical drug development and registration, but also become Roche's strategic highland for global innovative drug concept and empirical work More innovative drugs will be developed for the first time in China and promoted to the world Recently, Lilly pharmaceutical released the third quarter of 2019 financial report During the reporting period, the company's global sales volume was US $5.48 billion, a year-on-year increase of 3.2%; its net profit was US $1.25 billion, a year-on-year increase of 9.1% In the financial report conference call, Josh smiley, chief financial officer, revealed that sales in China increased by 33% year on year in this quarter, which was an important contribution to sales growth of Lilly in markets outside the United States by 15% Structural adjustment, new drug listing, sale and price reduction of expired patent drugs, abolition of R & D Center Lilly is gradually integrating China into the world's synchronized territory and into the "rules of the game" in China Since July, Lilly's new drugs, which have been on the market for a short time, have been "on the line" in China: in early July, the weekly preparation of GLP-1 receptor agonist doyida (dulaglutide) and the 2mg tablet of alexin (baretinib) for the treatment of adult moderate to severe active rheumatoid arthritis have been on the market in China; on September 4, it was used for the treatment of moderate to severe plaque psoriasis suitable for systematic treatment or phototherapy Tuozi (iqzumab injection) for adult patients was approved by the National Drug Administration (nmpa) Previously, Lilly, which has realized that the overall growth rate of the domestic diabetes market has slowed down significantly, has started to "lose weight" in China, including the abolition of research and development centers, the sale of expired patent medicine business, etc After experiencing the power of the first round of belt quantity purchase, Lilly reduced the price of pemetrexed nationwide In March, Lilly pemetrexed disodium took the lead in price adjustment in Zhejiang Province, which also made Lilly become the first original research pharmaceutical enterprise in China to actively apply for price reduction, and was shortlisted in the second round with a low attitude Finally, pemetrexed won the bid with a competitive price of 809 yuan / box (100mg), compared with“ The price of 4 + 7 "11 pilot cities will be reduced by 70% In April this year, Lilly sold to Yiteng pharmaceutical its rights in mainland China of its antibiotic product, secrolo, and its production plant in Suzhou According to the financial report, in terms of future profits in the Chinese market, Tuozi is expected to go on sale in the next few months The drug was approved in China for the first time in September this year for the treatment of adult patients with moderate and severe plaque psoriasis Among the unapproved products, verzenio (abemaciclib), an inhibitor of CDK 4 / 6, and rituximab, a biologically similar drug promoted in cooperation with Cinda bio, have entered the stage of NDA application and NDA approval, and are expected to take the lead in the market As the best multinational pharmaceutical company in China, the growth of AstraZeneca's business in China has naturally attracted much attention On October 24, AstraZeneca released the first three quarters of 2019 performance report, with product sales revenue of US $17.315 billion, a year-on-year growth of 17%, including the third quarter product sales revenue of US $6.132 billion, a year-on-year growth of 18% Among them, China's revenue in the first three quarters was US $3.691 billion, up 37% year on year Among them, the sales revenue in the field of tumor was US $1.023 billion, up 67% year on year, and that in the field of new cvrm was US $359 million, up 88% year on year In the new round of belt purchase, rosuvastatin of AstraZeneca was not selected, but gefitinib of AstraZeneca successfully won the bid of "4 + 7" after reducing the price by 75% last year, and continued to win the bid in this round of belt purchase at the same price Therefore, in the conference call, AstraZeneca executives pointed out that even after the 4 + 7 volume procurement nationwide expansion or expansion to more varieties in 2020, the company's China business is expected to maintain a growth rate of "more than 10%" However, AstraZeneca is more likely to rely on the promotion of new drugs and Medicare catalogs than on expired patents Last year, a total of 10 products of AstraZeneca were included in the national essential drug catalog, including: brinta (ticagre), symbiort (xinbike), Pulmicort (Pulmicort Lingshu) and farxiga (andatang) Farxiga, lynparza and roxadustat have also entered the price negotiation stage of the medical insurance catalogue